Doctors find Alkermes schizophrenia data ‘somewhat’ meaningful: Jefferies

Jefferies analyst Biren Amin says his firm performed a second survey of 35 practicing psychiatrists who treat adult schizophrenia following the Enlighten-2 readout from Alkermes. Doctors appear to find the Phase 3 data “somewhat clinically meaningful,” with a majority of potential prescriptions for ALKS 3831 converting from olanzapine and other atypicals in 2021, Amin tells investors in a research note. The survey shows that by 2021, about 13% of patients would be prescribed ALKS 3831, with about 50% of its share coming from conversion from other atypicals and 40% coming from olanzapine. The analyst adds that he did not take into account the potential influence of a branded price, which he notes could affect uptake. Amin has a Hold rating on Alkermes with a $43 price target.

https://thefly.com/landingPageNews.php?id=2851611